Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Intramuscular fat, contained within muscle tissue, increases the risk of serious heart disease, regardless of other risk ...

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

Incretins are intestinal hormones secreted in response to nutrient entry into the gut, inducing insulin secretion and inhibiting glucagon release. While this response is diminished in individuals with ...

Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make ...